Theranostic silica nanoparticles for selective and simultaneous delivery of paclitaxel and coumarin to hypoxic tumors.

Authors

Paula Rodrigo-Martínez, Lamiaa Mohamed Ahmed Ali, Carmen Coll, Magali Gary-Bobo, Jean-Yves Winum, Pau Arroyo, Jose A Sáez, Pablo Gaviña

Published in

International journal of pharmaceutics. Pages 127317. Aug 16, 2026. Epub Aug 16, 2026.

Abstract

Theranostic nanomaterials, that combine diagnostic imaging with drug delivery, have emerged as a promising alternative to conventional oncology therapy. Tumor hypoxia and the poor solubility of chemotherapeutics like paclitaxel (PTX) remain critical obstacles in oncology. To address these challenges, we have developed hypoxia-responsive theranostic mesoporous silica nanoparticles for the selective delivery of PTX and a coumarin fluorescent dye to hypoxic tumors. The silica nanocarrier is capped with a molecular gate containing a masked coumarin fluorophore attached to a nitro-containing self-immolative spacer. Upon exposure to nitroreductases (NTR), enzymes overexpressed in hypoxic tumor microenvironments, the gate undergoes a self-immolation reaction, triggering the simultaneous release of the cargo and the activation of coumarin fluorescence. This design allows for real-time monitoring of drug release. In vitro assays demonstrated that the nanocarriers selectively reduced the viability of A549 lung cancer cells under hypoxic conditions while exhibiting high biocompatibility with healthy THP-1 macrophages in normoxia. Moreover, in vivo studies using a zebrafish xenograft model confirmed effective tumor accumulation and significant tumor regression (34% reduction) compared to controls, with reduced systemic toxicity. This proof-of-concept establishes the potential of these NTR-responsive theranostic MSNs as versatile multifunctional nanocarriers integrating diagnostic tracking with targeted therapeutic release in hypoxic environments.

PMID:
42604719
Bibliographic data and abstract were imported from PubMed on 17 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.